Display options
Cite
Superko HR. Hypercholesterolemia and Dyslipidemia. Curr Treat Options Cardiovasc Med. 2000;2(2):173-187doi: 10.1007/s11936-000-0010-5.
Superko, H. R. (2000). Hypercholesterolemia and Dyslipidemia. Current treatment options in cardiovascular medicine, 2(2), 173-187. https://doi.org/10.1007/s11936-000-0010-5
Superko. "Hypercholesterolemia and Dyslipidemia." Current treatment options in cardiovascular medicine vol. 2,2 (2000): 173-187. doi: https://doi.org/10.1007/s11936-000-0010-5
Superko HR. Hypercholesterolemia and Dyslipidemia. Curr Treat Options Cardiovasc Med. 2000 Apr;2(2):173-187. doi: 10.1007/s11936-000-0010-5. PMID: 11096522.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Cardiovasc Med. 2000 Apr;2(2):173-187. doi: 10.1007/s11936-000-0010-5.

Hypercholesterolemia and Dyslipidemia.

Current treatment options in cardiovascular medicine

Superko

Affiliations

  1. Berkeley HeartLab, Inc., 1875 South Grant Street, Suite 700, San Mateo, CA 94402, USA.

PMID: 11096522 DOI: 10.1007/s11936-000-0010-5

Abstract

Disorders of cholesterol and lipoprotein metabolism are at the heart of atherosclerosis and coronary artery disease (CAD). CAD, however, is a metabolic disorder that involves a complex interaction between genetic susceptibility and environmental conditions. Despite considerable success in the treatment of hypercholesterolemia, atherosclerosis remains the leading cause of death in most Western countries. Although cholesterol-lowering trials have revealed a 25% to 30% reduction in clinical events, most patients continue to have events even when treated successfully with cholesterol-lowering medications (Fig. 1). This less-than-optimal result is partly because atherosclerosis is a multifactorial disease. Although disorders of lipoprotein metabolism are found in more than 80% of patients with CAD, these disorders are very heterogeneous, and single-drug therapy aimed at one disorder should not be expected to improve the disease status in most patients. Metabolic treatment still requires identification and treatment of patients with high cholesterol levels, but the focus has shifted to identifying high-risk patients in groups previously thought to be low risk, or to identifying disorders coexistent with high cholesterol levels that are not corrected by standard cholesterol-lowering medications (Table 1). The ability to detect high-risk CAD traits, which are often inherited, and to predict response to treatment has substantially improved in the past few years. These improvements allow identification of metabolic subgroups of patients, which can alter risk prediction and response to specific treatments. Sophisticated laboratory methods permit physicians to apply this knowledge to patient care and to enter a new era of CAD risk factor detection and treatment. These advances allow for a more scientific approach than did the previously standard epidemiologic risk factors and routine blood lipid profiles. The current state-of-the-art method of diagnosing and treating lipoprotein disorders has progressed beyond the standard "lipid profile," which includes total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol along with fasting triglyceride levels. Incorporating aspects of the atherogenic lipid profile (ALP), LDL subclass distribution, HDL subclass distribution, apo E isoforms, and lipoprotein (a) provides the interested clinician with the tools to create a more detailed and accurate diagnosis of lipoprotein disorders. Sophisticated laboratory tests are available to clinicians through technology transfer programs, as exemplified by the Lawrence Berkeley National Laboratory/Berkeley HeartLab collaboration, and allow clinicians access to research-quality laboratory tools. This has significant clinical relevance because the presence of these disorders guides treatment specific to the disorder(s). Appropriate treatment is more beneficial in subgroups exhibiting the disorder that the therapy is most likely to correct. A single drug or lifestyle therapy is no longer appropriate for all patients. The treatment must match the disorder.

References

  1. N Engl J Med. 1995 Nov 16;333(20):1301-7 - PubMed
  2. J Intern Med. 1989 Oct;226(4):271-6 - PubMed
  3. Artery. 1991;18(6):315-25 - PubMed
  4. Am J Cardiol. 1998 Nov 5;82(9A):34Q-46Q - PubMed
  5. J Clin Invest. 1983 Sep;72(3):743-7 - PubMed
  6. Circulation. 1996 Nov 1;94(9):2146-53 - PubMed
  7. Circulation. 1995 Feb 15;91(4):948-50 - PubMed
  8. JAMA. 1992 Jun 24;267(24):3326-9 - PubMed
  9. Arterioscler Thromb. 1991 Jan-Feb;11(1):174-82 - PubMed
  10. J Clin Invest. 1987 Apr;79(4):1110-9 - PubMed
  11. Arteriosclerosis. 1989 Jan-Feb;9(1 Suppl):I8-13 - PubMed
  12. Arterioscler Thromb. 1993 Aug;13(8):1139-58 - PubMed
  13. Arterioscler Thromb. 1994 Nov;14 (11):1730-6 - PubMed
  14. N Engl J Med. 1996 Oct 3;335(14):1001-9 - PubMed
  15. Am J Cardiol. 1984 Aug 27;54(5):20C-26C - PubMed
  16. Arteriosclerosis. 1988 Jan-Feb;8(1):1-21 - PubMed
  17. Arterioscler Thromb. 1991 Nov-Dec;11(6):1737-44 - PubMed
  18. Arteriosclerosis. 1989 May-Jun;9(3):335-44 - PubMed
  19. JAMA. 1997 Nov 12;278(18):1509-15 - PubMed
  20. Pediatr Res. 1993 Nov;34(5):670-4 - PubMed
  21. Proc Natl Acad Sci U S A. 1989 Jan;86(2):587-91 - PubMed
  22. Clin Chem. 1990 Jan;36(1):20-3 - PubMed
  23. J Clin Invest. 1986 Sep;78(3):815-21 - PubMed
  24. Am J Med. 1993 Jan;94(1):7-12 - PubMed
  25. Arterioscler Thromb. 1994 Feb;14(2):275-81 - PubMed
  26. Curr Opin Lipidol. 1996 Dec;7(6):363-8 - PubMed
  27. Science. 1981 Feb 6;211(4482):584-6 - PubMed
  28. Arterioscler Thromb. 1993 Dec;13(12):1728-37 - PubMed
  29. Int J Epidemiol. 1986 Mar;15(1):51-5 - PubMed
  30. Mol Cell Biochem. 1992 Aug 18;113(2):141-9 - PubMed
  31. FASEB J. 1995 Jun;9(9):768-76 - PubMed
  32. J Clin Invest. 1990 Jun;85(6):1709-15 - PubMed
  33. J Lipid Res. 1986 Mar;27(3):326-33 - PubMed
  34. Clin Chim Acta. 1981 Jul 18;114(1):45-52 - PubMed
  35. Arterioscler Thromb. 1993 Apr;13(4):579-89 - PubMed
  36. Am J Cardiol. 1994 Jun 1;73(15):1037-40 - PubMed
  37. Med Clin North Am. 1982 Mar;66(2):375-402 - PubMed
  38. Science. 1988 Apr 29;240(4852):622-30 - PubMed
  39. Am J Cardiol. 1998 Feb 26;81(4A):52B-59B - PubMed
  40. Arterioscler Thromb. 1994 Oct;14(10):1586-93 - PubMed
  41. JAMA. 1994 Apr 6;271(13):999-1003 - PubMed
  42. Circulation. 1996 Nov 15;94(10):2351-4 - PubMed
  43. J Clin Invest. 1973 Jul;52(7):1544-68 - PubMed
  44. JAMA. 1988 Jun 24;259(24):3579-86 - PubMed
  45. Circulation. 1997 Jan 7;95(1):69-75 - PubMed
  46. Curr Opin Cardiol. 1995 Jul;10(4):347-54 - PubMed
  47. Circulation. 1986 Oct;74(4):758-65 - PubMed
  48. Am J Med. 1994 Oct;97(4):323-31 - PubMed
  49. Int J Epidemiol. 1989;18(3 Suppl 1):S1-230 - PubMed
  50. J Clin Invest. 1987 Dec;80(6):1571-7 - PubMed
  51. Circulation. 1989 Nov;80(5):1313-9 - PubMed
  52. JAMA. 1995 Dec 13;274(22):1771-4 - PubMed
  53. Atherosclerosis. 1985 Nov;57(2-3):293-301 - PubMed
  54. Lancet. 1994 Nov 19;344(8934):1383-9 - PubMed
  55. Proc Natl Acad Sci U S A. 1980 Jan;77(1):604-8 - PubMed
  56. Science. 1993 Aug 13;261(5123):921-3 - PubMed
  57. Circulation. 1982 Dec;66(6):1176-8 - PubMed
  58. JAMA. 1984 Jan 20;251(3):351-64 - PubMed
  59. Diabetes. 1988 Dec;37(12):1595-607 - PubMed
  60. Metabolism. 1993 Nov;42(11):1461-7 - PubMed
  61. Circulation. 1966 Oct;34(4):679-97 - PubMed
  62. Metabolism. 1991 Feb;40(2):217-21 - PubMed
  63. Am Heart J. 1987 Feb;113(2 Pt 2):589-97 - PubMed
  64. Circulation. 1974 Mar;49(3):476-88 - PubMed
  65. JAMA. 1990 Dec 19;264(23 ):3007-12 - PubMed
  66. Curr Opin Lipidol. 1994 Oct;5(5):339-49 - PubMed
  67. Lancet. 1991 Jan 26;337(8735):203-4 - PubMed
  68. N Engl J Med. 1986 Mar 13;314(11):671-7 - PubMed

Publication Types